Potential drug-drug interactions associated with drugs currently proposed for COVID-19 treatment in patients receiving other treatments.
Identifieur interne : 000922 ( Main/Exploration ); précédent : 000921; suivant : 000923Potential drug-drug interactions associated with drugs currently proposed for COVID-19 treatment in patients receiving other treatments.
Auteurs : Florian Lemaitre [France] ; Caroline Solas [France] ; Matthieu Grégoire [France] ; Laurence Lagarce [France] ; Laure Elens [Belgique] ; Elisabeth Polard [France] ; Béatrice Saint-Salvi [France] ; Agnès Sommet [France] ; Michel Tod [France] ; Chantal Barin-Le Guellec [France]Source :
- Fundamental & clinical pharmacology [ 1472-8206 ] ; 2020.
Descripteurs français
- KwdFr :
- Agents cardiovasculaires (pharmacologie), Analgésiques (pharmacologie), Anti-inflammatoires (pharmacologie), Antiasthmatiques (pharmacologie), Antibactériens (pharmacologie), Anticoagulants (pharmacologie), Antinéoplasiques (pharmacologie), Antituberculeux (pharmacologie), Antiviraux (pharmacologie), Appréciation des risques (MeSH), Betacoronavirus (MeSH), Hormones thyroïdiennes (pharmacologie), Humains (MeSH), Hydroxychloroquine (pharmacologie), Hypoglycémiants (pharmacologie), Hypolipémiants (pharmacologie), Infections à coronavirus (traitement médicamenteux), Interactions médicamenteuses (MeSH), Interféron bêta-1b (pharmacologie), Médicaments sur ordonnance (pharmacocinétique), Médicaments sur ordonnance (pharmacologie), Pandémies (MeSH), Pneumopathie virale (traitement médicamenteux), Psychoanaleptiques (pharmacologie), Récepteurs aux interleukines (antagonistes et inhibiteurs).
- MESH :
- antagonistes et inhibiteurs : Récepteurs aux interleukines.
- pharmacocinétique : Médicaments sur ordonnance.
- pharmacologie : Agents cardiovasculaires, Analgésiques, Anti-inflammatoires, Antiasthmatiques, Antibactériens, Anticoagulants, Antinéoplasiques, Antituberculeux, Antiviraux, Hormones thyroïdiennes, Hydroxychloroquine, Hypoglycémiants, Hypolipémiants, Interféron bêta-1b, Médicaments sur ordonnance, Psychoanaleptiques.
- traitement médicamenteux : Infections à coronavirus, Pneumopathie virale.
- Appréciation des risques, Betacoronavirus, Humains, Interactions médicamenteuses, Pandémies.
English descriptors
- KwdEn :
- Analgesics (pharmacology), Anti-Asthmatic Agents (pharmacology), Anti-Bacterial Agents (pharmacology), Anti-Inflammatory Agents (pharmacology), Anticoagulants (pharmacology), Antineoplastic Agents (pharmacology), Antitubercular Agents (pharmacology), Antiviral Agents (pharmacology), Betacoronavirus (MeSH), Cardiovascular Agents (pharmacology), Coronavirus Infections (drug therapy), Drug Interactions (MeSH), Humans (MeSH), Hydroxychloroquine (pharmacology), Hypoglycemic Agents (pharmacology), Hypolipidemic Agents (pharmacology), Interferon beta-1b (pharmacology), Pandemics (MeSH), Pneumonia, Viral (drug therapy), Prescription Drugs (pharmacokinetics), Prescription Drugs (pharmacology), Psychotropic Drugs (pharmacology), Receptors, Interleukin (antagonists & inhibitors), Risk Assessment (MeSH), Thyroid Hormones (pharmacology).
- MESH :
- chemical , antagonists & inhibitors : Receptors, Interleukin.
- chemical , pharmacokinetics : Prescription Drugs.
- chemical , pharmacology : Analgesics, Anti-Asthmatic Agents, Anti-Bacterial Agents, Anti-Inflammatory Agents, Anticoagulants, Antineoplastic Agents, Antitubercular Agents, Antiviral Agents, Cardiovascular Agents, Hydroxychloroquine, Hypoglycemic Agents, Hypolipidemic Agents, Interferon beta-1b, Prescription Drugs, Psychotropic Drugs, Thyroid Hormones.
- drug therapy : Coronavirus Infections, Pneumonia, Viral.
- Betacoronavirus, Drug Interactions, Humans, Pandemics, Risk Assessment.
Abstract
Patients with COVID-19 are sometimes already being treated for one or more other chronic conditions, especially if they are elderly. Introducing a treatment against COVID-19, either on an outpatient basis or during hospitalization for more severe cases, raises the question of potential drug-drug interactions. Here, we analyzed the potential or proven risk of the co-administration of drugs used for the most common chronic diseases and those currently offered as treatment or undergoing therapeutic trials for COVID-19. Practical recommendations are offered, where possible.
DOI: 10.1111/fcp.12586
PubMed: 32603486
PubMed Central: PMC7361515
Affiliations:
- Belgique, France
- Auvergne-Rhône-Alpes, Centre-Val de Loire, Limousin, Midi-Pyrénées, Nouvelle-Aquitaine, Occitanie (région administrative), Pays de la Loire, Provence-Alpes-Côte d'Azur, Province du Brabant wallon, Rhône-Alpes, Région Bretagne, Région Centre, Région wallonne, Île-de-France
- Louvain-la-Neuve
- Université catholique de Louvain, Université de Tours
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Potential drug-drug interactions associated with drugs currently proposed for COVID-19 treatment in patients receiving other treatments.</title><author><name sortKey="Lemaitre, Florian" sort="Lemaitre, Florian" uniqKey="Lemaitre F" first="Florian" last="Lemaitre">Florian Lemaitre</name><affiliation wicri:level="3"><nlm:affiliation>Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, Rennes, F-35000, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, Rennes, F-35000</wicri:regionArea><placeName><region type="region" nuts="2">Région Bretagne</region></placeName></affiliation><affiliation wicri:level="3"><nlm:affiliation>INSERM, Centre d'Investigation Clinique, CIC 1414, Rennes, F-35000, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>INSERM, Centre d'Investigation Clinique, CIC 1414, Rennes, F-35000</wicri:regionArea><placeName><region type="region" nuts="2">Région Bretagne</region></placeName></affiliation></author><author><name sortKey="Solas, Caroline" sort="Solas, Caroline" uniqKey="Solas C" first="Caroline" last="Solas">Caroline Solas</name><affiliation wicri:level="3"><nlm:affiliation>Aix-Marseille University, APHM, UMR "Emergence des Pathologies Virales" Inserm 1207 IRD 190, Laboratoire de Pharmacocinétique et Toxicologie, Hôpital La Timone, Marseille, 13005, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Aix-Marseille University, APHM, UMR "Emergence des Pathologies Virales" Inserm 1207 IRD 190, Laboratoire de Pharmacocinétique et Toxicologie, Hôpital La Timone, Marseille, 13005</wicri:regionArea><placeName><region type="region" nuts="2">Provence-Alpes-Côte d'Azur</region></placeName></affiliation></author><author><name sortKey="Gregoire, Matthieu" sort="Gregoire, Matthieu" uniqKey="Gregoire M" first="Matthieu" last="Grégoire">Matthieu Grégoire</name><affiliation wicri:level="3"><nlm:affiliation>Clinical Pharmacology Department, CHU Nantes, Nantes Cedex 1, Nantes, 44093, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Clinical Pharmacology Department, CHU Nantes, Nantes Cedex 1, Nantes, 44093</wicri:regionArea><placeName><region type="region" nuts="2">Pays de la Loire</region></placeName></affiliation><affiliation wicri:level="3"><nlm:affiliation>UMR INSERM 1235, The Enteric Nervous System in Gut and Brain Disorders, University of Nantes, Nantes Cedex 1, Nantes, 44093, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>UMR INSERM 1235, The Enteric Nervous System in Gut and Brain Disorders, University of Nantes, Nantes Cedex 1, Nantes, 44093</wicri:regionArea><placeName><region type="region" nuts="2">Pays de la Loire</region></placeName></affiliation></author><author><name sortKey="Lagarce, Laurence" sort="Lagarce, Laurence" uniqKey="Lagarce L" first="Laurence" last="Lagarce">Laurence Lagarce</name><affiliation wicri:level="3"><nlm:affiliation>Service de Pharmacologie-Toxicologie et Pharmacovigilance, Centre Hospitalo-Universitaire d'Angers, Angers, 49100, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service de Pharmacologie-Toxicologie et Pharmacovigilance, Centre Hospitalo-Universitaire d'Angers, Angers, 49100</wicri:regionArea><placeName><region type="region" nuts="2">Pays de la Loire</region></placeName></affiliation></author><author><name sortKey="Elens, Laure" sort="Elens, Laure" uniqKey="Elens L" first="Laure" last="Elens">Laure Elens</name><affiliation wicri:level="4"><nlm:affiliation>Integrated Pharmacometrics, Pharmacogenomics and Pharmacokinetics (PMGK), Louvain Drug Research Institute (LDRI), Université Catholique de Louvain (UCL), Louvain, Belgique.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Integrated Pharmacometrics, Pharmacogenomics and Pharmacokinetics (PMGK), Louvain Drug Research Institute (LDRI), Université Catholique de Louvain (UCL), Louvain</wicri:regionArea><orgName type="university">Université catholique de Louvain</orgName><placeName><settlement type="city">Louvain-la-Neuve</settlement><region type="region" nuts="1">Région wallonne</region><region type="province" nuts="1">Province du Brabant wallon</region></placeName></affiliation><affiliation wicri:level="4"><nlm:affiliation>Louvain Center for Toxicology and Applied Pharmacology (LTAP), Institut de Recherche Expérimentale et Clinique (IREC), Université Catholique de Louvain (UCL), Louvain, Belgique.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Louvain Center for Toxicology and Applied Pharmacology (LTAP), Institut de Recherche Expérimentale et Clinique (IREC), Université Catholique de Louvain (UCL), Louvain</wicri:regionArea><orgName type="university">Université catholique de Louvain</orgName><placeName><settlement type="city">Louvain-la-Neuve</settlement><region type="region" nuts="1">Région wallonne</region><region type="province" nuts="1">Province du Brabant wallon</region></placeName></affiliation></author><author><name sortKey="Polard, Elisabeth" sort="Polard, Elisabeth" uniqKey="Polard E" first="Elisabeth" last="Polard">Elisabeth Polard</name><affiliation wicri:level="3"><nlm:affiliation>Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, Rennes, F-35000, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, Rennes, F-35000</wicri:regionArea><placeName><region type="region" nuts="2">Région Bretagne</region></placeName></affiliation><affiliation wicri:level="3"><nlm:affiliation>INSERM, Centre d'Investigation Clinique, CIC 1414, Rennes, F-35000, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>INSERM, Centre d'Investigation Clinique, CIC 1414, Rennes, F-35000</wicri:regionArea><placeName><region type="region" nuts="2">Région Bretagne</region></placeName></affiliation></author><author><name sortKey="Saint Salvi, Beatrice" sort="Saint Salvi, Beatrice" uniqKey="Saint Salvi B" first="Béatrice" last="Saint-Salvi">Béatrice Saint-Salvi</name><affiliation wicri:level="3"><nlm:affiliation>Medical Interactions Unit, Agence National de Sécurité du Médicaments et des produits de santé, Saint-Denis, 93200, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Medical Interactions Unit, Agence National de Sécurité du Médicaments et des produits de santé, Saint-Denis, 93200</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region></placeName></affiliation></author><author><name sortKey="Sommet, Agnes" sort="Sommet, Agnes" uniqKey="Sommet A" first="Agnès" last="Sommet">Agnès Sommet</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medical and Clinical Pharmacology, Centre of PharmacoVigilance and Pharmacoepidemiology, INSERM UMR 1027, CIC 1426, Toulouse University Hospital, Faculty of Medicine, University of Toulouse, Toulouse, 31000, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Medical and Clinical Pharmacology, Centre of PharmacoVigilance and Pharmacoepidemiology, INSERM UMR 1027, CIC 1426, Toulouse University Hospital, Faculty of Medicine, University of Toulouse, Toulouse, 31000</wicri:regionArea><placeName><region type="region" nuts="2">Occitanie (région administrative)</region><region type="old region" nuts="2">Midi-Pyrénées</region></placeName></affiliation></author><author><name sortKey="Tod, Michel" sort="Tod, Michel" uniqKey="Tod M" first="Michel" last="Tod">Michel Tod</name><affiliation wicri:level="3"><nlm:affiliation>Pharmacy, Croix-Rousse Hospital, Lyon, 69005, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Pharmacy, Croix-Rousse Hospital, Lyon, 69005</wicri:regionArea><placeName><region type="region" nuts="2">Auvergne-Rhône-Alpes</region><region type="old region" nuts="2">Rhône-Alpes</region></placeName></affiliation><affiliation wicri:level="3"><nlm:affiliation>ISPB, University Lyon 1, Lyon, 69005, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>ISPB, University Lyon 1, Lyon, 69005</wicri:regionArea><placeName><region type="region" nuts="2">Auvergne-Rhône-Alpes</region><region type="old region" nuts="2">Rhône-Alpes</region></placeName></affiliation></author><author><name sortKey="Barin Le Guellec, Chantal" sort="Barin Le Guellec, Chantal" uniqKey="Barin Le Guellec C" first="Chantal" last="Barin-Le Guellec">Chantal Barin-Le Guellec</name><affiliation wicri:level="3"><nlm:affiliation>Laboratoire de Biochimie et de Biologie Moléculaire, CHU de Tours, Tours, F37044, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Laboratoire de Biochimie et de Biologie Moléculaire, CHU de Tours, Tours, F37044</wicri:regionArea><placeName><region type="region" nuts="2">Centre-Val de Loire</region><region type="old region" nuts="2">Région Centre</region></placeName></affiliation><affiliation wicri:level="4"><nlm:affiliation>Université de Tours, Tours, F-37044, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Université de Tours, Tours, F-37044</wicri:regionArea><placeName><region type="region" nuts="2">Centre-Val de Loire</region><region type="old region" nuts="2">Région Centre</region></placeName><orgName type="university">Université de Tours</orgName></affiliation><affiliation wicri:level="3"><nlm:affiliation>INSERM, IPPRITT, U1248, Limoges, F-87000, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>INSERM, IPPRITT, U1248, Limoges, F-87000</wicri:regionArea><placeName><region type="region" nuts="2">Nouvelle-Aquitaine</region><region type="old region" nuts="2">Limousin</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32603486</idno><idno type="pmid">32603486</idno><idno type="doi">10.1111/fcp.12586</idno><idno type="pmc">PMC7361515</idno><idno type="wicri:Area/Main/Corpus">000B56</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000B56</idno><idno type="wicri:Area/Main/Curation">000B56</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000B56</idno><idno type="wicri:Area/Main/Exploration">000B56</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Potential drug-drug interactions associated with drugs currently proposed for COVID-19 treatment in patients receiving other treatments.</title><author><name sortKey="Lemaitre, Florian" sort="Lemaitre, Florian" uniqKey="Lemaitre F" first="Florian" last="Lemaitre">Florian Lemaitre</name><affiliation wicri:level="3"><nlm:affiliation>Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, Rennes, F-35000, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, Rennes, F-35000</wicri:regionArea><placeName><region type="region" nuts="2">Région Bretagne</region></placeName></affiliation><affiliation wicri:level="3"><nlm:affiliation>INSERM, Centre d'Investigation Clinique, CIC 1414, Rennes, F-35000, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>INSERM, Centre d'Investigation Clinique, CIC 1414, Rennes, F-35000</wicri:regionArea><placeName><region type="region" nuts="2">Région Bretagne</region></placeName></affiliation></author><author><name sortKey="Solas, Caroline" sort="Solas, Caroline" uniqKey="Solas C" first="Caroline" last="Solas">Caroline Solas</name><affiliation wicri:level="3"><nlm:affiliation>Aix-Marseille University, APHM, UMR "Emergence des Pathologies Virales" Inserm 1207 IRD 190, Laboratoire de Pharmacocinétique et Toxicologie, Hôpital La Timone, Marseille, 13005, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Aix-Marseille University, APHM, UMR "Emergence des Pathologies Virales" Inserm 1207 IRD 190, Laboratoire de Pharmacocinétique et Toxicologie, Hôpital La Timone, Marseille, 13005</wicri:regionArea><placeName><region type="region" nuts="2">Provence-Alpes-Côte d'Azur</region></placeName></affiliation></author><author><name sortKey="Gregoire, Matthieu" sort="Gregoire, Matthieu" uniqKey="Gregoire M" first="Matthieu" last="Grégoire">Matthieu Grégoire</name><affiliation wicri:level="3"><nlm:affiliation>Clinical Pharmacology Department, CHU Nantes, Nantes Cedex 1, Nantes, 44093, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Clinical Pharmacology Department, CHU Nantes, Nantes Cedex 1, Nantes, 44093</wicri:regionArea><placeName><region type="region" nuts="2">Pays de la Loire</region></placeName></affiliation><affiliation wicri:level="3"><nlm:affiliation>UMR INSERM 1235, The Enteric Nervous System in Gut and Brain Disorders, University of Nantes, Nantes Cedex 1, Nantes, 44093, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>UMR INSERM 1235, The Enteric Nervous System in Gut and Brain Disorders, University of Nantes, Nantes Cedex 1, Nantes, 44093</wicri:regionArea><placeName><region type="region" nuts="2">Pays de la Loire</region></placeName></affiliation></author><author><name sortKey="Lagarce, Laurence" sort="Lagarce, Laurence" uniqKey="Lagarce L" first="Laurence" last="Lagarce">Laurence Lagarce</name><affiliation wicri:level="3"><nlm:affiliation>Service de Pharmacologie-Toxicologie et Pharmacovigilance, Centre Hospitalo-Universitaire d'Angers, Angers, 49100, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service de Pharmacologie-Toxicologie et Pharmacovigilance, Centre Hospitalo-Universitaire d'Angers, Angers, 49100</wicri:regionArea><placeName><region type="region" nuts="2">Pays de la Loire</region></placeName></affiliation></author><author><name sortKey="Elens, Laure" sort="Elens, Laure" uniqKey="Elens L" first="Laure" last="Elens">Laure Elens</name><affiliation wicri:level="4"><nlm:affiliation>Integrated Pharmacometrics, Pharmacogenomics and Pharmacokinetics (PMGK), Louvain Drug Research Institute (LDRI), Université Catholique de Louvain (UCL), Louvain, Belgique.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Integrated Pharmacometrics, Pharmacogenomics and Pharmacokinetics (PMGK), Louvain Drug Research Institute (LDRI), Université Catholique de Louvain (UCL), Louvain</wicri:regionArea><orgName type="university">Université catholique de Louvain</orgName><placeName><settlement type="city">Louvain-la-Neuve</settlement><region type="region" nuts="1">Région wallonne</region><region type="province" nuts="1">Province du Brabant wallon</region></placeName></affiliation><affiliation wicri:level="4"><nlm:affiliation>Louvain Center for Toxicology and Applied Pharmacology (LTAP), Institut de Recherche Expérimentale et Clinique (IREC), Université Catholique de Louvain (UCL), Louvain, Belgique.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Louvain Center for Toxicology and Applied Pharmacology (LTAP), Institut de Recherche Expérimentale et Clinique (IREC), Université Catholique de Louvain (UCL), Louvain</wicri:regionArea><orgName type="university">Université catholique de Louvain</orgName><placeName><settlement type="city">Louvain-la-Neuve</settlement><region type="region" nuts="1">Région wallonne</region><region type="province" nuts="1">Province du Brabant wallon</region></placeName></affiliation></author><author><name sortKey="Polard, Elisabeth" sort="Polard, Elisabeth" uniqKey="Polard E" first="Elisabeth" last="Polard">Elisabeth Polard</name><affiliation wicri:level="3"><nlm:affiliation>Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, Rennes, F-35000, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, Rennes, F-35000</wicri:regionArea><placeName><region type="region" nuts="2">Région Bretagne</region></placeName></affiliation><affiliation wicri:level="3"><nlm:affiliation>INSERM, Centre d'Investigation Clinique, CIC 1414, Rennes, F-35000, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>INSERM, Centre d'Investigation Clinique, CIC 1414, Rennes, F-35000</wicri:regionArea><placeName><region type="region" nuts="2">Région Bretagne</region></placeName></affiliation></author><author><name sortKey="Saint Salvi, Beatrice" sort="Saint Salvi, Beatrice" uniqKey="Saint Salvi B" first="Béatrice" last="Saint-Salvi">Béatrice Saint-Salvi</name><affiliation wicri:level="3"><nlm:affiliation>Medical Interactions Unit, Agence National de Sécurité du Médicaments et des produits de santé, Saint-Denis, 93200, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Medical Interactions Unit, Agence National de Sécurité du Médicaments et des produits de santé, Saint-Denis, 93200</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region></placeName></affiliation></author><author><name sortKey="Sommet, Agnes" sort="Sommet, Agnes" uniqKey="Sommet A" first="Agnès" last="Sommet">Agnès Sommet</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medical and Clinical Pharmacology, Centre of PharmacoVigilance and Pharmacoepidemiology, INSERM UMR 1027, CIC 1426, Toulouse University Hospital, Faculty of Medicine, University of Toulouse, Toulouse, 31000, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Medical and Clinical Pharmacology, Centre of PharmacoVigilance and Pharmacoepidemiology, INSERM UMR 1027, CIC 1426, Toulouse University Hospital, Faculty of Medicine, University of Toulouse, Toulouse, 31000</wicri:regionArea><placeName><region type="region" nuts="2">Occitanie (région administrative)</region><region type="old region" nuts="2">Midi-Pyrénées</region></placeName></affiliation></author><author><name sortKey="Tod, Michel" sort="Tod, Michel" uniqKey="Tod M" first="Michel" last="Tod">Michel Tod</name><affiliation wicri:level="3"><nlm:affiliation>Pharmacy, Croix-Rousse Hospital, Lyon, 69005, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Pharmacy, Croix-Rousse Hospital, Lyon, 69005</wicri:regionArea><placeName><region type="region" nuts="2">Auvergne-Rhône-Alpes</region><region type="old region" nuts="2">Rhône-Alpes</region></placeName></affiliation><affiliation wicri:level="3"><nlm:affiliation>ISPB, University Lyon 1, Lyon, 69005, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>ISPB, University Lyon 1, Lyon, 69005</wicri:regionArea><placeName><region type="region" nuts="2">Auvergne-Rhône-Alpes</region><region type="old region" nuts="2">Rhône-Alpes</region></placeName></affiliation></author><author><name sortKey="Barin Le Guellec, Chantal" sort="Barin Le Guellec, Chantal" uniqKey="Barin Le Guellec C" first="Chantal" last="Barin-Le Guellec">Chantal Barin-Le Guellec</name><affiliation wicri:level="3"><nlm:affiliation>Laboratoire de Biochimie et de Biologie Moléculaire, CHU de Tours, Tours, F37044, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Laboratoire de Biochimie et de Biologie Moléculaire, CHU de Tours, Tours, F37044</wicri:regionArea><placeName><region type="region" nuts="2">Centre-Val de Loire</region><region type="old region" nuts="2">Région Centre</region></placeName></affiliation><affiliation wicri:level="4"><nlm:affiliation>Université de Tours, Tours, F-37044, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Université de Tours, Tours, F-37044</wicri:regionArea><placeName><region type="region" nuts="2">Centre-Val de Loire</region><region type="old region" nuts="2">Région Centre</region></placeName><orgName type="university">Université de Tours</orgName></affiliation><affiliation wicri:level="3"><nlm:affiliation>INSERM, IPPRITT, U1248, Limoges, F-87000, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>INSERM, IPPRITT, U1248, Limoges, F-87000</wicri:regionArea><placeName><region type="region" nuts="2">Nouvelle-Aquitaine</region><region type="old region" nuts="2">Limousin</region></placeName></affiliation></author></analytic><series><title level="j">Fundamental & clinical pharmacology</title><idno type="eISSN">1472-8206</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Analgesics (pharmacology)</term><term>Anti-Asthmatic Agents (pharmacology)</term><term>Anti-Bacterial Agents (pharmacology)</term><term>Anti-Inflammatory Agents (pharmacology)</term><term>Anticoagulants (pharmacology)</term><term>Antineoplastic Agents (pharmacology)</term><term>Antitubercular Agents (pharmacology)</term><term>Antiviral Agents (pharmacology)</term><term>Betacoronavirus (MeSH)</term><term>Cardiovascular Agents (pharmacology)</term><term>Coronavirus Infections (drug therapy)</term><term>Drug Interactions (MeSH)</term><term>Humans (MeSH)</term><term>Hydroxychloroquine (pharmacology)</term><term>Hypoglycemic Agents (pharmacology)</term><term>Hypolipidemic Agents (pharmacology)</term><term>Interferon beta-1b (pharmacology)</term><term>Pandemics (MeSH)</term><term>Pneumonia, Viral (drug therapy)</term><term>Prescription Drugs (pharmacokinetics)</term><term>Prescription Drugs (pharmacology)</term><term>Psychotropic Drugs (pharmacology)</term><term>Receptors, Interleukin (antagonists & inhibitors)</term><term>Risk Assessment (MeSH)</term><term>Thyroid Hormones (pharmacology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Agents cardiovasculaires (pharmacologie)</term><term>Analgésiques (pharmacologie)</term><term>Anti-inflammatoires (pharmacologie)</term><term>Antiasthmatiques (pharmacologie)</term><term>Antibactériens (pharmacologie)</term><term>Anticoagulants (pharmacologie)</term><term>Antinéoplasiques (pharmacologie)</term><term>Antituberculeux (pharmacologie)</term><term>Antiviraux (pharmacologie)</term><term>Appréciation des risques (MeSH)</term><term>Betacoronavirus (MeSH)</term><term>Hormones thyroïdiennes (pharmacologie)</term><term>Humains (MeSH)</term><term>Hydroxychloroquine (pharmacologie)</term><term>Hypoglycémiants (pharmacologie)</term><term>Hypolipémiants (pharmacologie)</term><term>Infections à coronavirus (traitement médicamenteux)</term><term>Interactions médicamenteuses (MeSH)</term><term>Interféron bêta-1b (pharmacologie)</term><term>Médicaments sur ordonnance (pharmacocinétique)</term><term>Médicaments sur ordonnance (pharmacologie)</term><term>Pandémies (MeSH)</term><term>Pneumopathie virale (traitement médicamenteux)</term><term>Psychoanaleptiques (pharmacologie)</term><term>Récepteurs aux interleukines (antagonistes et inhibiteurs)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Receptors, Interleukin</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Prescription Drugs</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Analgesics</term><term>Anti-Asthmatic Agents</term><term>Anti-Bacterial Agents</term><term>Anti-Inflammatory Agents</term><term>Anticoagulants</term><term>Antineoplastic Agents</term><term>Antitubercular Agents</term><term>Antiviral Agents</term><term>Cardiovascular Agents</term><term>Hydroxychloroquine</term><term>Hypoglycemic Agents</term><term>Hypolipidemic Agents</term><term>Interferon beta-1b</term><term>Prescription Drugs</term><term>Psychotropic Drugs</term><term>Thyroid Hormones</term></keywords><keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Récepteurs aux interleukines</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="pharmacocinétique" xml:lang="fr"><term>Médicaments sur ordonnance</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Agents cardiovasculaires</term><term>Analgésiques</term><term>Anti-inflammatoires</term><term>Antiasthmatiques</term><term>Antibactériens</term><term>Anticoagulants</term><term>Antinéoplasiques</term><term>Antituberculeux</term><term>Antiviraux</term><term>Hormones thyroïdiennes</term><term>Hydroxychloroquine</term><term>Hypoglycémiants</term><term>Hypolipémiants</term><term>Interféron bêta-1b</term><term>Médicaments sur ordonnance</term><term>Psychoanaleptiques</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Betacoronavirus</term><term>Drug Interactions</term><term>Humans</term><term>Pandemics</term><term>Risk Assessment</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Appréciation des risques</term><term>Betacoronavirus</term><term>Humains</term><term>Interactions médicamenteuses</term><term>Pandémies</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Patients with COVID-19 are sometimes already being treated for one or more other chronic conditions, especially if they are elderly. Introducing a treatment against COVID-19, either on an outpatient basis or during hospitalization for more severe cases, raises the question of potential drug-drug interactions. Here, we analyzed the potential or proven risk of the co-administration of drugs used for the most common chronic diseases and those currently offered as treatment or undergoing therapeutic trials for COVID-19. Practical recommendations are offered, where possible.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32603486</PMID><DateCompleted><Year>2020</Year><Month>09</Month><Day>17</Day></DateCompleted><DateRevised><Year>2020</Year><Month>09</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1472-8206</ISSN><JournalIssue CitedMedium="Internet"><Volume>34</Volume><Issue>5</Issue><PubDate><Year>2020</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Fundamental & clinical pharmacology</Title><ISOAbbreviation>Fundam Clin Pharmacol</ISOAbbreviation></Journal><ArticleTitle>Potential drug-drug interactions associated with drugs currently proposed for COVID-19 treatment in patients receiving other treatments.</ArticleTitle><Pagination><MedlinePgn>530-547</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/fcp.12586</ELocationID><Abstract><AbstractText>Patients with COVID-19 are sometimes already being treated for one or more other chronic conditions, especially if they are elderly. Introducing a treatment against COVID-19, either on an outpatient basis or during hospitalization for more severe cases, raises the question of potential drug-drug interactions. Here, we analyzed the potential or proven risk of the co-administration of drugs used for the most common chronic diseases and those currently offered as treatment or undergoing therapeutic trials for COVID-19. Practical recommendations are offered, where possible.</AbstractText><CopyrightInformation>© 2020 Société Française de Pharmacologie et de Thérapeutique.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lemaitre</LastName><ForeName>Florian</ForeName><Initials>F</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-0908-3629</Identifier><AffiliationInfo><Affiliation>Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, Rennes, F-35000, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>INSERM, Centre d'Investigation Clinique, CIC 1414, Rennes, F-35000, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Solas</LastName><ForeName>Caroline</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Aix-Marseille University, APHM, UMR "Emergence des Pathologies Virales" Inserm 1207 IRD 190, Laboratoire de Pharmacocinétique et Toxicologie, Hôpital La Timone, Marseille, 13005, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grégoire</LastName><ForeName>Matthieu</ForeName><Initials>M</Initials><Identifier Source="ORCID">https://orcid.org/0000-0003-1232-5761</Identifier><AffiliationInfo><Affiliation>Clinical Pharmacology Department, CHU Nantes, Nantes Cedex 1, Nantes, 44093, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UMR INSERM 1235, The Enteric Nervous System in Gut and Brain Disorders, University of Nantes, Nantes Cedex 1, Nantes, 44093, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lagarce</LastName><ForeName>Laurence</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Service de Pharmacologie-Toxicologie et Pharmacovigilance, Centre Hospitalo-Universitaire d'Angers, Angers, 49100, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elens</LastName><ForeName>Laure</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Integrated Pharmacometrics, Pharmacogenomics and Pharmacokinetics (PMGK), Louvain Drug Research Institute (LDRI), Université Catholique de Louvain (UCL), Louvain, Belgique.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Louvain Center for Toxicology and Applied Pharmacology (LTAP), Institut de Recherche Expérimentale et Clinique (IREC), Université Catholique de Louvain (UCL), Louvain, Belgique.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Polard</LastName><ForeName>Elisabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, Rennes, F-35000, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>INSERM, Centre d'Investigation Clinique, CIC 1414, Rennes, F-35000, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saint-Salvi</LastName><ForeName>Béatrice</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Medical Interactions Unit, Agence National de Sécurité du Médicaments et des produits de santé, Saint-Denis, 93200, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sommet</LastName><ForeName>Agnès</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medical and Clinical Pharmacology, Centre of PharmacoVigilance and Pharmacoepidemiology, INSERM UMR 1027, CIC 1426, Toulouse University Hospital, Faculty of Medicine, University of Toulouse, Toulouse, 31000, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tod</LastName><ForeName>Michel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Pharmacy, Croix-Rousse Hospital, Lyon, 69005, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>ISPB, University Lyon 1, Lyon, 69005, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barin-Le Guellec</LastName><ForeName>Chantal</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Laboratoire de Biochimie et de Biologie Moléculaire, CHU de Tours, Tours, F37044, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Université de Tours, Tours, F-37044, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>INSERM, IPPRITT, U1248, Limoges, F-87000, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>French Society of Pharmacology, Therapeutics (SFPT), the International Association of Therapeutic Drug Monitoring, Clinical Toxicology (IATDMCT)</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>07</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Fundam Clin Pharmacol</MedlineTA><NlmUniqueID>8710411</NlmUniqueID><ISSNLinking>0767-3981</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000700">Analgesics</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018927">Anti-Asthmatic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000893">Anti-Inflammatory Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000995">Antitubercular Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002317">Cardiovascular Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007004">Hypoglycemic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000960">Hypolipidemic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D055553">Prescription Drugs</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011619">Psychotropic Drugs</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018123">Receptors, Interleukin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013963">Thyroid Hormones</NameOfSubstance></Chemical><Chemical><RegistryNumber>145155-23-3</RegistryNumber><NameOfSubstance UI="D000068576">Interferon beta-1b</NameOfSubstance></Chemical><Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber><NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName><SupplMeshName Type="Protocol" UI="C000705127">COVID-19 drug treatment</SupplMeshName><SupplMeshName Type="Organism" UI="C000656484">severe acute respiratory syndrome coronavirus 2</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Fundam Clin Pharmacol. 2020 Oct;34(5):528-529</RefSource><PMID Version="1">32615022</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000700" MajorTopicYN="N">Analgesics</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018927" MajorTopicYN="N">Anti-Asthmatic Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000893" MajorTopicYN="N">Anti-Inflammatory Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000925" MajorTopicYN="N">Anticoagulants</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000995" MajorTopicYN="N">Antitubercular Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002317" MajorTopicYN="N">Cardiovascular Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004347" MajorTopicYN="N">Drug Interactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007004" MajorTopicYN="N">Hypoglycemic Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000960" MajorTopicYN="N">Hypolipidemic Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000068576" MajorTopicYN="N">Interferon beta-1b</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055553" MajorTopicYN="N">Prescription Drugs</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011619" MajorTopicYN="N">Psychotropic Drugs</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018123" MajorTopicYN="N">Receptors, Interleukin</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013963" MajorTopicYN="N">Thyroid Hormones</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">adverse events</Keyword><Keyword MajorTopicYN="N">hydroxychloroquine</Keyword><Keyword MajorTopicYN="N">lopinavir</Keyword><Keyword MajorTopicYN="N">pharmacodynamics</Keyword><Keyword MajorTopicYN="N">pharmacokinetics</Keyword><Keyword MajorTopicYN="N">therapeutic drug monitoring</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>05</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>06</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>06</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>7</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>9</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>7</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32603486</ArticleId><ArticleId IdType="doi">10.1111/fcp.12586</ArticleId><ArticleId IdType="pmc">PMC7361515</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>Zhu N., Zhang D., Wang W. et al. A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med. (2020) 382 727-733.</Citation></Reference><Reference><Citation>Simonnet A., Chetboun M., Poissy J. et al. High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation. Obesity (2020) 28 1195-1199.</Citation></Reference><Reference><Citation>Ji D., Zhang D., Xu J. et al. Prediction for progression risk in patients with COVID-19 pneumonia: the CALL score. Clin. Infect. Dis. (2020) ciaa414 [Online ahead of print].</Citation></Reference><Reference><Citation>Zhou F., Yu T., Du R. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet (2020) 395 1054-1062.</Citation></Reference><Reference><Citation>Yin S., Huang M., Li D., Tang N. Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2. J. Thromb. Thrombolysis. (2020) https://doi.org/10.1007/s11239-020-02105-8 [Online ahead of print].</Citation></Reference><Reference><Citation>Fried J.A., Ramasubbu K., Bhatt R. et al. The variety of cardiovascular presentations of COVID-19. Circulation (2020) 141 1930-1936.</Citation></Reference><Reference><Citation>Zhang Y., Zheng L., Liu L., Zhao M., Xiao J., Zhao Q. Liver impairment in COVID-19 patients: a retrospective analysis of 115 cases from a single center in Wuhan city, China. Liver Int. (2020) https://doi.org/10.1111/liv.14455 [Online ahead of print].</Citation></Reference><Reference><Citation>Sanders J.M., Monogue M.L., Jodlowski T.Z., Cutrell J.B. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA (2020) https://doi.org/10.1001/jama.2020.6019 [Online ahead of print].</Citation></Reference><Reference><Citation>Morgan E.T. Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics. Clin. Pharmacol. Ther. (2009) 85 434-438.</Citation></Reference><Reference><Citation>Ofotokun I., Lennox J.L., Eaton M.E. et al. Immune activation mediated change in alpha-1-acid glycoprotein: impact on total and free lopinavir plasma exposure. J. Clin. Pharmacol. (2011) 51 1539-1548.</Citation></Reference><Reference><Citation>Tornio A., Filppula A.M., Niemi M., Backman J.T. Clinical studies on drug-drug interactions involving metabolism and transport: methodology, pitfalls, and interpretation. Clin. Pharmacol. Ther. (2019) 105 1345-1361.</Citation></Reference><Reference><Citation>Tod M., Goutelle S., Bleyzac N., Bourguignon L. A generic model for quantitative prediction of interactions mediated by efflux transporters and cytochromes: application to P-glycoprotein and cytochrome 3A4. Clin. Pharmacokinet. (2019) 58 503-523.</Citation></Reference><Reference><Citation>Société Française de Pharmacologie et Thérapeutique. Hot topics COVID-19 dans therapies. [Cited 2020 Apr 30]. Available from: https://sfpt-fr.org/groupes-de-travail/m%C3%A9dicaments-covid-19/1166-hot-topics-covid19.</Citation></Reference><Reference><Citation>Boulware D.R., Pullen M.F., Bangdiwala A.S. et al. A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19. N. Engl. J. Med. (2020) https://doi.org/10.1056/NEJMoa2016638 [Online ahead of print].</Citation></Reference><Reference><Citation>Agence Nationale de Sécurité du Médicament. Plaquenil, Résumé des caractéristiques du produit [Internet]. [Cited 2020 Apr 23]. Available from: http://agence-prd.ansm.sante.fr/php/ecodex/frames.php?specid=67767535&typedoc=R&ref=R0351462.htm.</Citation></Reference><Reference><Citation>Tett S.E., Cutler D.J., Day R.O., Brown K.F. A dose-ranging study of the pharmacokinetics of hydroxy-chloroquine following intravenous administration to healthy volunteers. Br. J. Clin. Pharmacol. (1988) 26 303-313.</Citation></Reference><Reference><Citation>Du Y.-X., Chen X.-P. Favipiravir: pharmacokinetics and concerns about clinical trials for 2019-nCoV infection. Clin. Pharmacol. Ther. (2020) https://doi.org/10.1002/cpt.1844 [Online ahead of print].</Citation></Reference><Reference><Citation>University of Liverpool. COVID-19 drug interactions [Internet]. [Cited 2020 Apr 23]. Available from: https://www.covid19-druginteractions.org/.</Citation></Reference><Reference><Citation>Drug Bank. Remdesivir [Internet]. [Cited 2020 Apr 23]. Available from: https://www.drugbank.ca/drugs/DB14761.</Citation></Reference><Reference><Citation>EMA. Kaletra product information [Internet]. [Cited 2020 Apr 23]. Available from: https://www.ema.europa.eu/en/documents/product-information/kaletra-epar-product-information_en.pdf.</Citation></Reference><Reference><Citation>Hung I.F.-N., Lung K.-C., Tso E.Y.-K. et al. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet (2020) 395 1695-1704.</Citation></Reference><Reference><Citation>Schmitt C., Kuhn B., Zhang X., Kivitz A.J., Grange S. Disease-drug-drug interaction involving tocilizumab and simvastatin in patients with rheumatoid arthritis. Clin. Pharmacol. Ther. (2011) 89 735-740.</Citation></Reference><Reference><Citation>Lee E.B., Daskalakis N., Xu C. et al. Disease-drug interaction of sarilumab and simvastatin in patients with rheumatoid arthritis. Clin. Pharmacokinet. (2017) 56 607-615.</Citation></Reference><Reference><Citation>EMA. Kineret product information [Internet]. [Cited 2020 Jun 17]. Available from: https://www.ema.europa.eu/en/documents/product-information/kineret-epar-product-information_en.pdf.</Citation></Reference><Reference><Citation>Agence Nationale de Sécurité du Médicament. Zithromax, Résumé des caractéristiques du produit [Internet]. [Cited 2020 Apr 23]. Available from: http://agence-prd.ansm.sante.fr/php/ecodex/frames.php?specid=65740799&typedoc=R&ref=R0338983.htm.</Citation></Reference><Reference><Citation>Menzel M., Akbarshahi H., Bjermer L., Uller L. Azithromycin induces anti-viral effects in cultured bronchial epithelial cells from COPD patients. Sci. Rep. (2016) 6 28698.</Citation></Reference><Reference><Citation>Lane J., Weaver J., Kostka K. et al. Safety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid wide-spread use for COVID- 19: a multinational, network cohort and self- controlled case series study. medRxiv. (2020)</Citation></Reference><Reference><Citation>EMA. Olumiant product information [Internet]. [Cited 2020 Jun 17]. Available from: https://www.ema.europa.eu/en/documents/product-information/olumiant-epar-product-information_en.pdf.</Citation></Reference><Reference><Citation>Favalli E.G., Biggioggero M., Maioli G., Caporali R. Baricitinib for COVID-19: a suitable treatment? Lancet Infect. Dis. (2020) https://doi.org/10.1016/S1473-3099(20)30262-0 [Online ahead of print].</Citation></Reference><Reference><Citation>Richardson P., Griffin I., Tucker C. et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet (2020) 395 e30-e31.</Citation></Reference><Reference><Citation>Gong L., Stamer U.M., Tzvetkov M.V., Altman R.B., Klein T.E. PharmGKB summary: tramadol pathway. Pharmacogenet. Genomics (2014) 24 374-380.</Citation></Reference><Reference><Citation>Owusu Obeng A., Hamadeh I., Smith M. Review of opioid pharmacogenetics and considerations for pain management. Pharmacotherapy (2017) 37 1105-1121.</Citation></Reference><Reference><Citation>Huddart R., Clarke M., Altman R.B., Klein T.E. PharmGKB summary: oxycodone pathway, pharmacokinetics. Pharmacogenet. Genomics (2018) 28 230-237.</Citation></Reference><Reference><Citation>SFAR. Traitement anticoagulant pour la prévention du risque thrombotique chez un patient hospitalisé avec Covid-19 et surveillance de l'hémostase [Internet]. [Cited 2020 Apr 23]. Available from: https://sfar.org/traitement-anticoagulant-pour-la-prevention-du-risque-thrombotique-chez-un-patient-hospitalise-avec-covid-19-et-surveillance-de-lhemostase/.</Citation></Reference><Reference><Citation>Marsousi N., Daali Y., Fontana P. et al. Impact of boosted antiretroviral therapy on the pharmacokinetics and efficacy of clopidogrel and prasugrel active metabolites. Clin. Pharmacokinet. (2018) 57 1347-1354.</Citation></Reference><Reference><Citation>Elsby R., Hilgendorf C., Fenner K. Understanding the critical disposition pathways of statins to assess drug-drug interaction risk during drug development: it's not just about OATP1B1. Clin. Pharmacol. Ther. (2012) 92 584-598.</Citation></Reference><Reference><Citation>Puech R., Gagnieu M.-C., Planus C. et al. Extreme bradycardia due to multiple drug-drug interactions in a patient with HIV post-exposure prophylaxis containing lopinavir-ritonavir. Br. J. Clin. Pharmacol. (2011) 71 621-623.</Citation></Reference><Reference><Citation>Naccarato M., Yoong D., la Porte C., Fong I. Amiodarone and concurrent antiretroviral therapy: a case report and review of the literature. Antivir. Ther. (2014) 19 329-339.</Citation></Reference><Reference><Citation>Ding R., Tayrouz Y., Riedel K.-D. et al. Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers. Clin. Pharmacol. Ther. (2004) 76 73-84.</Citation></Reference><Reference><Citation>Fichtenbaum C.J., Gerber J.G. Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection. Clin. Pharmacokinet. (2002) 41 1195-1211.</Citation></Reference><Reference><Citation>Tagaya Y., Okada S., Hisada T., Niijima Y., Yamada M. Interstitial pneumonia during administration of dipeptidyl peptidase-4 inhibitors. J. Diabetes. (2016) 8 442.</Citation></Reference><Reference><Citation>Kuse N., Abe S., Kuribayashi H. et al. A case of vildagliptin-induced interstitial pneumonia. Respir. Med. Case Rep. (2016) 18 10-13.</Citation></Reference><Reference><Citation>EMA. Edurant product information [Internet]. [Cited 2020 Apr 23]. Available from: https://www.ema.europa.eu/en/documents/product-information/edurant-epar-product-information_en.pdf.</Citation></Reference><Reference><Citation>EMA. Celsentri product information [Internet]. [Cited 2020 Apr 23]. Available from: https://www.ema.europa.eu/en/documents/product-information/celsentri-epar-product-information_en.pdf.</Citation></Reference><Reference><Citation>Song I., Min S.S., Borland J. et al. The effect of lopinavir/ritonavir and darunavir/ritonavir on the HIV integrase inhibitor S/GSK1349572 in healthy participants. J. Clin. Pharmacol. (2011) 51 237-242.</Citation></Reference><Reference><Citation>Rhame F., Long M., Acosta E. RAL-KAL: pharmacokinetics of coadministered raltegravir and lopinavir-ritonavir in healthy adults. 9th International Workshop on Clinical Pharmacology of HIV therapy, 2008.</Citation></Reference><Reference><Citation>Solas C., Poizot-Martin I., Drogoul M.-P. et al. Therapeutic drug monitoring of lopinavir/ritonavir given alone or with a non-nucleoside reverse transcriptase inhibitor. Br. J. Clin. Pharmacol. (2004) 57 436-440.</Citation></Reference><Reference><Citation>EMA. Recommendations on compassionate use of Remdesivir for COVID-19 [Internet]. [Cited 2020 Apr 23]. Available from: https://www.ema.europa.eu/en/news/ema-provides-recommendations-compassionate-use-remdesivir-covid-19.</Citation></Reference><Reference><Citation>Fontaine H., Lazarus A., Pol S. et al. Bradyarrhythmias associated with sofosbuvir treatment. N. Engl. J. Med. (2015) 373 1886-1888.</Citation></Reference><Reference><Citation>EMA. Vosevi product information [Internet]. [Cited 2020 Apr 23]. Available from: https://www.ema.europa.eu/en/documents/product-information/vosevi-epar-product-information_en.pdf.</Citation></Reference><Reference><Citation>Kosloski M.P., Oberoi R., Wang S. et al. Drug-drug interactions of glecaprevir and pibrentasvir coadministered with human immunodeficiency virus antiretrovirals. J. Infect. Dis. (2020) 221 223-231.</Citation></Reference><Reference><Citation>Yu J., Zhou Z., Tay-Sontheimer J., Levy R.H., Ragueneau-Majlessi I. Risk of clinically relevant pharmacokinetic-based drug-drug interactions with drugs approved by the U.S. Food and Drug Administration between 2013 and 2016. Drug Metab. Dispos. Biol. Fate Chem. (2018) 46 835-845.</Citation></Reference><Reference><Citation>Sheahan T.P., Sims A.C., Graham R.L. et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci. Transl. Med. (2017) 9 eaal3653.</Citation></Reference><Reference><Citation>Pandie M., Wiesner L., McIlleron H. et al. Drug-drug interactions between bedaquiline and the antiretrovirals lopinavir/ritonavir and nevirapine in HIV-infected patients with drug-resistant TB. J. Antimicrob. Chemother. (2016) 71 1037-1040.</Citation></Reference><Reference><Citation>Spano J.-P., Poizot-Martin I., Costagliola D. et al. Non-AIDS-related malignancies: expert consensus review and practical applications from the multidisciplinary CANCERVIH Working Group. Ann. Oncol. (2016) 27 397-408.</Citation></Reference><Reference><Citation>Abbar B., Veyri M., Solas C., Poizot-Martin I., Spano J.-P. HIV and cancer: update 2020. Bull. Cancer (2020) 107 21-29.</Citation></Reference><Reference><Citation>Courtillat E., Veyri M., Spano J.-P., Solas C. Drug interactions between antiretroviral and chemo-/ targeted therapy. Innov. Therap. Oncologie (2019) 6 318-322.</Citation></Reference><Reference><Citation>Ikitimur B., Cosansu K., Karadag B. et al. Long-term impact of different immunosuppressive drugs on QT and PR intervals in renal transplant patients. Ann. Noninvasive Electrocardiol. (2015) 20 426-432.</Citation></Reference><Reference><Citation>Urva S., Bouillaud E., Delaney R., Jappe A., Cheung W. A phase I study evaluating the effect of everolimus on the pharmacokinetics of midazolam in healthy subjects. J. Clin. Pharmacol. (2013) 53 444-450.</Citation></Reference><Reference><Citation>Jain A.B., Venkataramanan R., Eghtesad B. et al. Effect of coadministered lopinavir and ritonavir (Kaletra) on tacrolimus blood concentration in liver transplantation patients. Liver Transplant. (2003) 9 954-960.</Citation></Reference><Reference><Citation>Frassetto L.A., Browne M., Cheng A. et al. Immunosuppressant pharmacokinetics and dosing modifications in HIV-1 infected liver and kidney transplant recipients. Am. J. Transplant. (2007) 7 2816-2820.</Citation></Reference><Reference><Citation>Frassetto L., Baluom M., Jacobsen W. et al. Cyclosporine pharmacokinetics and dosing modifications in human immunodeficiency virus-infected liver and kidney transplant recipients. Transplantation (2005) 80 13-17.</Citation></Reference><Reference><Citation>Krown S.E., Roy D., Lee J.Y. et al. Rapamycin with antiretroviral therapy in AIDS-associated Kaposi sarcoma: an AIDS Malignancy Consortium study. J. Acquir. Immune Defic. Syndr. (2012) 59 447-454.</Citation></Reference><Reference><Citation>Elens L., Langman L.J., Hesselink D.A. et al. Pharmacologic treatment of transplant recipients infected with SARS-CoV-2: considerations regarding therapeutic drug monitoring and drug-drug interactions. Ther. Drug Monit. (2020) 42 360-368.</Citation></Reference><Reference><Citation>Long T.J., Cosgrove P.A., Dunn R.T. et al. Modeling therapeutic antibody-small molecule drug-drug interactions using a three-dimensional perfusable human liver coculture platform. Drug Metab. Dispos. Biol. Fate Chem. (2016) 44 1940-1948.</Citation></Reference><Reference><Citation>Javelot H., El-Hage W., Meyer G., Becker G., Michel B., Hingray C. COVID-19 and (hydroxy)chloroquine-azithromycin combination: should we take the risk for our patients? Br. J. Clin. Pharmacol. (2020) 86 1176-1178.</Citation></Reference><Reference><Citation>Castro V.M., Clements C.C., Murphy S.N. et al. QT interval and antidepressant use: a cross sectional study of electronic health records. BMJ (2013) 346 f288.</Citation></Reference><Reference><Citation>Schlit A.-F., Delaunois A., Colomar A. et al. Risk of QT prolongation and torsade de pointes associated with exposure to hydroxyzine: re-evaluation of an established drug. Pharmacol. Res. Perspect. (2017) 5 e00309.</Citation></Reference><Reference><Citation>Taylor D.M. Antipsychotics and QT prolongation. Acta Psychiatr. Scand. (2003) 107 85-95.</Citation></Reference><Reference><Citation>Cormac I., Brown A., Creasey S., Ferriter M., Huckstep B. A retrospective evaluation of the impact of total smoking cessation on psychiatric inpatients taking clozapine. Acta Psychiatr. Scand. (2010) 121 393-397.</Citation></Reference><Reference><Citation>Bondolfi G., Morel F., Crettol S., Rachid F., Baumann P., Eap C.B. Increased clozapine plasma concentrations and side effects induced by smoking cessation in 2 CYP1A2 genotyped patients. Ther. Drug Monit. (2005) 27 539-543.</Citation></Reference><Reference><Citation>Wahawisan J., Kolluru S., Nguyen T., Molina C., Speake J. Methadone toxicity due to smoking cessation-a case report on the drug-drug interaction involving cytochrome P450 isoenzyme 1A2. Ann. Pharmacother. (2011) 45 e34.</Citation></Reference><Reference><Citation>Krantz M.J., Rowan S.B., Mehler P.S. Cocaine-related torsade de pointes in a methadone maintenance patient. J. Addict. Dis. (2005) 24 53-60.</Citation></Reference><Reference><Citation>Taylor D., Parish D., Thompson L., Cavaliere M. Cocaine induced prolongation of the QT interval. Emerg. Med. J. (2004) 21 252-253.</Citation></Reference><Reference><Citation>Ausband S.C., Goodman P.E. An unusual case of clarithromycin associated ergotism. J. Emerg. Med. (2001) 21 411-413.</Citation></Reference><Reference><Citation>Harvey C.J., Lloyd M.E., Bateman N.T., Hughes G.R. Influence of rifampicin on hydroxychloroquine. Clin. Exp. Rheumatol. (1995) 13 536.</Citation></Reference><Reference><Citation>Munera Y., Hugues F.C., Le Jeunne C., Pays J.F. Interaction of thyroxine sodium with antimalarial drugs. BMJ (1997) 314 1593.</Citation></Reference><Reference><Citation>Foisy M.M., Yakiwchuk E.M.K., Chiu I., Singh A.E. Adrenal suppression and Cushing's syndrome secondary to an interaction between ritonavir and fluticasone: a review of the literature. HIV Med. (2008) 9 389-396.</Citation></Reference><Reference><Citation>Cazzola M., Testi R., Matera M.G. Clinical pharmacokinetics of salmeterol. Clin. Pharmacokinet. (2002) 41 19-30.</Citation></Reference><Reference><Citation>Varma M.V., Kimoto E., Scialis R. et al. Transporter-mediated hepatic uptake plays an important role in the pharmacokinetics and drug-drug interactions of montelukast. Clin. Pharmacol. Ther. (2017) 101 406-415.</Citation></Reference><Reference><Citation>SFAR. Recommandations d'experts portant sur la prise en charge en réanimation des patients en période d'épidémie à SARS-CoV2 [Internet]. [Cited 2020 Apr 23]. Available from: https://sfar.org/recommandations-dexperts-portant-sur-la-prise-en-charge-en-reanimation-des-patients-en-periode-depidemie-a-sars-cov2/.</Citation></Reference><Reference><Citation>SFAR. La sédation du patient Covid en réanimation: quelles spécificités? [Internet]. [Cited 2020 Apr 23]. Available from: https://sfar.org/download/la-sedation-du-patient-covid-en-reanimation-quelles-specificites/.</Citation></Reference><Reference><Citation>Mehta P., McAuley D.F., Brown M., Sanchez E., Tattersall R.S., Manson J.J. COVID- 19: consider cytokine storm syndromes and immunosuppression. Lancet (2020) 395 1033-1034.</Citation></Reference><Reference><Citation>Tagami T., Ong M.E.H. Extravascular lung water measurements in acute respiratory distress syndrome: why, how, and when? Curr. Opin. Crit. Care. (2018) 24 209-215.</Citation></Reference><Reference><Citation>Opal S.M., van der Poll T. Endothelial barrier dysfunction in septic shock. J. Intern. Med. (2015) 277 277-293.</Citation></Reference><Reference><Citation>Roberts J.A., Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit. Care Med. (2009) 37 840-851; quiz 859.</Citation></Reference><Reference><Citation>Bleyzac N., Bourguignon L., Goutelle S., Tod M.DDI predictor website, Academic version [Internet]. [Cited 2020 Apr 23]. Available from: https://www.ddi-predictor.org/.</Citation></Reference><Reference><Citation>Repessé X., Charron C., Vieillard-Baron A. Acute respiratory distress syndrome: the heart side of the moon. Curr. Opin. Crit. Care. (2016) 22 38-44.</Citation></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>Belgique</li><li>France</li></country><region><li>Auvergne-Rhône-Alpes</li><li>Centre-Val de Loire</li><li>Limousin</li><li>Midi-Pyrénées</li><li>Nouvelle-Aquitaine</li><li>Occitanie (région administrative)</li><li>Pays de la Loire</li><li>Provence-Alpes-Côte d'Azur</li><li>Province du Brabant wallon</li><li>Rhône-Alpes</li><li>Région Bretagne</li><li>Région Centre</li><li>Région wallonne</li><li>Île-de-France</li></region><settlement><li>Louvain-la-Neuve</li></settlement><orgName><li>Université catholique de Louvain</li><li>Université de Tours</li></orgName></list><tree><country name="France"><region name="Région Bretagne"><name sortKey="Lemaitre, Florian" sort="Lemaitre, Florian" uniqKey="Lemaitre F" first="Florian" last="Lemaitre">Florian Lemaitre</name></region><name sortKey="Barin Le Guellec, Chantal" sort="Barin Le Guellec, Chantal" uniqKey="Barin Le Guellec C" first="Chantal" last="Barin-Le Guellec">Chantal Barin-Le Guellec</name><name sortKey="Barin Le Guellec, Chantal" sort="Barin Le Guellec, Chantal" uniqKey="Barin Le Guellec C" first="Chantal" last="Barin-Le Guellec">Chantal Barin-Le Guellec</name><name sortKey="Barin Le Guellec, Chantal" sort="Barin Le Guellec, Chantal" uniqKey="Barin Le Guellec C" first="Chantal" last="Barin-Le Guellec">Chantal Barin-Le Guellec</name><name sortKey="Gregoire, Matthieu" sort="Gregoire, Matthieu" uniqKey="Gregoire M" first="Matthieu" last="Grégoire">Matthieu Grégoire</name><name sortKey="Gregoire, Matthieu" sort="Gregoire, Matthieu" uniqKey="Gregoire M" first="Matthieu" last="Grégoire">Matthieu Grégoire</name><name sortKey="Lagarce, Laurence" sort="Lagarce, Laurence" uniqKey="Lagarce L" first="Laurence" last="Lagarce">Laurence Lagarce</name><name sortKey="Lemaitre, Florian" sort="Lemaitre, Florian" uniqKey="Lemaitre F" first="Florian" last="Lemaitre">Florian Lemaitre</name><name sortKey="Polard, Elisabeth" sort="Polard, Elisabeth" uniqKey="Polard E" first="Elisabeth" last="Polard">Elisabeth Polard</name><name sortKey="Polard, Elisabeth" sort="Polard, Elisabeth" uniqKey="Polard E" first="Elisabeth" last="Polard">Elisabeth Polard</name><name sortKey="Saint Salvi, Beatrice" sort="Saint Salvi, Beatrice" uniqKey="Saint Salvi B" first="Béatrice" last="Saint-Salvi">Béatrice Saint-Salvi</name><name sortKey="Solas, Caroline" sort="Solas, Caroline" uniqKey="Solas C" first="Caroline" last="Solas">Caroline Solas</name><name sortKey="Sommet, Agnes" sort="Sommet, Agnes" uniqKey="Sommet A" first="Agnès" last="Sommet">Agnès Sommet</name><name sortKey="Tod, Michel" sort="Tod, Michel" uniqKey="Tod M" first="Michel" last="Tod">Michel Tod</name><name sortKey="Tod, Michel" sort="Tod, Michel" uniqKey="Tod M" first="Michel" last="Tod">Michel Tod</name></country><country name="Belgique"><region name="Région wallonne"><name sortKey="Elens, Laure" sort="Elens, Laure" uniqKey="Elens L" first="Laure" last="Elens">Laure Elens</name></region><name sortKey="Elens, Laure" sort="Elens, Laure" uniqKey="Elens L" first="Laure" last="Elens">Laure Elens</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidFranceV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000922 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000922 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidFranceV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32603486
|texte= Potential drug-drug interactions associated with drugs currently proposed for COVID-19 treatment in patients receiving other treatments.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32603486" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidFranceV1
| This area was generated with Dilib version V0.6.37. |  |